Novel Detection and Clinical Utility of Serum-Derived Extracellular Vesicle in Angiosarcoma
DOI:
https://doi.org/10.2340/actadv.v105.40902Keywords:
Angiosarcoma, Serum, Extracellular vesicle, MicroRNA, BiomarkerAbstract
Cutaneous angiosarcoma is a rare and highly aggressive skin malignancy. The aim of this study is to explore the alteration of serum-derived extracellular vesicle (EV) in angiosarcoma patients and to evaluate its clinical utility as a novel circulating biomarker. In a microarray analysis to examine the differential expression of specific EV-associated microRNAs in sera between cutaneous angiosarcoma patients and healthy controls, 73 microRNAs with significant upregulation and 100 microRNAs with significant downregulation, respectively, were identified in patients with angio-sarcoma. Among them, quantitative PCR confirmed that miR-184, miR-3925-5p, miR-3926, and miR-5703 were upregulated in sera of cutaneous angiosarcoma patients compared with those of healthy controls and melanoma patients. Additionally, these 4 microRNAs were expressed more highly in angiosarcoma cell lines compared with normal human endothelial cell lines and were prone to elevate along with disease progression. Furthermore, a gene analysis predicted that the target gene set of microRNAs might affect the regulation of TP53 via the epigenetic regulation of MECP2. Taken together, these 4 extracellular vesicle-associated microRNAs in circulation serve as a promising liquid biomarker to identify angiosarcoma patients and trace disease progression.
Downloads
References
Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Am J Pathol 1999; 154: 385-394.
https://doi.org/10.1016/S0002-9440(10)65285-6 DOI: https://doi.org/10.1016/S0002-9440(10)65285-6
Bi S, Chen S, Wu B, Cen Y, Chen J. The effectiveness of different treatment modalities of cutaneous angiosarcoma: results from meta-analysis and observational data from SEER Database. Front Oncol 2021; 11: 627113.
https://doi.org/10.3389/fonc.2021.627113 DOI: https://doi.org/10.3389/fonc.2021.627113
Patel AM, Ryu JH. Angiosarcoma in the Lung. Chest 1993; 103: 1531-1535.
https://doi.org/10.1378/chest.103.5.1531 DOI: https://doi.org/10.1378/chest.103.5.1531
Zhang C, Xu G, Liu Z, Xu Y, Lin F, Baklaushev VP, et al. Epidemiology, tumor characteristics and survival in patients with angiosarcoma in the United States: a population-based study of 4537 cases. Jpn J Clin Oncol 2019; 49: 1092-1099.
https://doi.org/10.1093/jjco/hyz113 DOI: https://doi.org/10.1093/jjco/hyz113
Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci 2006; 103: 9136-9141.
https://doi.org/10.1073/pnas.0508889103 DOI: https://doi.org/10.1073/pnas.0508889103
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8: 467-77.
https://doi.org/10.1038/nrclinonc.2011.76 DOI: https://doi.org/10.1038/nrclinonc.2011.76
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
https://doi.org/10.1016/j.cell.2004.12.035 DOI: https://doi.org/10.1016/j.cell.2004.12.035
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
https://doi.org/10.1101/gr.082701.108 DOI: https://doi.org/10.1101/gr.082701.108
Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203-1217.
https://doi.org/10.1016/j.cell.2006.07.031 DOI: https://doi.org/10.1016/j.cell.2006.07.031
Annese T, Tamma R, De Giorgis M, Ribatti D. microRNAs biogenesis, functions and role in tumor angiogenesis. Front Oncol 2020; 10: 581007
https://doi.org/10.3389/fonc.2020.581007 DOI: https://doi.org/10.3389/fonc.2020.581007
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
https://doi.org/10.1016/j.ccr.2006.01.025 DOI: https://doi.org/10.1016/j.ccr.2006.01.025
Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches [published correction appears in J Extracell Vesicles 2024; 13: e12451]. J Extracell Vesicles 2024; 13: e12404.
https://doi.org/10.1002/jev2.12451 DOI: https://doi.org/10.1002/jev2.12451
Li B, Cao Y, Sun M, Feng H. Expression, regulation, and function of exosome‐derived miRNAs in cancer progression and therapy. FASEB J 2021; 35: e21916.
https://doi.org/10.1096/fj.202100294RR DOI: https://doi.org/10.1096/fj.202100294RR
Urabe F, Kosaka N, Ito K, Kimura T, Egawa S, Ochiya T. Extracellular vesicles as biomarkers and therapeutic targets for cancer. Am J Physiol Cell Physiol 2020; 318: C29-C39.
https://doi.org/10.1152/ajpcell.00280.2019 DOI: https://doi.org/10.1152/ajpcell.00280.2019
Kohama I, Kosaka N, Chikuda H, Ochiya T. An insight into the roles of MicroRNAs and exosomes in sarcoma. Cancers 2019; 11: 428.
https://doi.org/10.3390/cancers11030428 DOI: https://doi.org/10.3390/cancers11030428
Chen Y, Kuang D, Zhao X, Chen D, Wang X, Yang Q, et al. miR-497-5p inhibits cell proliferation and invasion by targeting KCa3.1 in angiosarcoma. Oncotarget 2016; 7: 58148-58161.
https://doi.org/10.18632/oncotarget.11252 DOI: https://doi.org/10.18632/oncotarget.11252
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat commun 2019; 10: 1523.
https://doi.org/10.1038/s41467-019-09234-6 DOI: https://doi.org/10.1038/s41467-019-09234-6
Wu G, Haw R. Functional interaction network construction and analysis for disease discovery. Methods Mol Biol 2017; 1558: 235-253.
https://doi.org/10.1007/978-1-4939-6783-4_11 DOI: https://doi.org/10.1007/978-1-4939-6783-4_11
Mendenhall WM, Mendenhall CM, Werning JW, Reith JD, Mendenhall NP. Cutaneous angiosarcoma. Am J Clin Oncol 2006; 29: 524-528.
https://doi.org/10.1097/01.coc.0000227544.01779.52 DOI: https://doi.org/10.1097/01.coc.0000227544.01779.52
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer 2018; 17: 147.
https://doi.org/10.1186/s12943-018-0897-7 DOI: https://doi.org/10.1186/s12943-018-0897-7
Masoudi MS, Mehrabian E, Mirzaei H. MiR‐21: A key player in glioblastoma pathogenesis. J Cell Biochem 2017; 119: 1285-1290.
https://doi.org/10.1002/jcb.26300 DOI: https://doi.org/10.1002/jcb.26300
Liu B, Shyr Y, Cai J, Liu Q. Interplay between miRNAs and host genes and their role in cancer. Brief Funct Genomics 2019; 18: 255-266.
https://doi.org/10.1093/bfgp/elz002 DOI: https://doi.org/10.1093/bfgp/elz002
Tengda L, Shuping L, Mingli G, Jie G, Yun L, Weiwei Z, et al. Serum exosomal microRNAs as potent circulating biomarkers for melanoma. Melanoma Res 2018; 28: 295-303.
https://doi.org/10.1097/CMR.0000000000000450 DOI: https://doi.org/10.1097/CMR.0000000000000450
Pfeffer SR, Grossmann KF, Cassidy PB, Yang CH, Fan M, Kopelovich L, et al. Detection of exosomal miRNAs in the plasma of melanoma patients. J Clin Med 2015; 4: 2012-2027.
https://doi.org/10.3390/jcm4121957 DOI: https://doi.org/10.3390/jcm4121957
Alegre E, Sanmamed MF, Rodriguez C, Carranza O, Martín-Algarra S, González A. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med 2014; 138: 828-832.
https://doi.org/10.5858/arpa.2013-0134-OA DOI: https://doi.org/10.5858/arpa.2013-0134-OA
Xiao D, Barry S, Kmetz D, Egger M, Pan J, Rai SN, et al. Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment. Cancer Lett 2016; 376: 318-327.
https://doi.org/10.1016/j.canlet.2016.03.050 DOI: https://doi.org/10.1016/j.canlet.2016.03.050
Li J, Chen J, Wang S, Li P, Zheng C, Zhou X, et al. Blockage of transferred exosome‐shuttled miR‐494 inhibits melanoma growth and metastasis. J Cell Physiol 2019; 234: 15763-15774.
https://doi.org/10.1002/jcp.28234 DOI: https://doi.org/10.1002/jcp.28234
Nejati-Koshki K, Roberts C-T, Babaei G, Rastegar M. The Epigenetic reader methyl-CpG-binding protein 2 (MeCP2) is an emerging oncogene in cancer biology. Cancers 2023; 15: 2683.
https://doi.org/10.3390/cancers15102683 DOI: https://doi.org/10.3390/cancers15102683
Basset-Séguin N, Molès JP, Mils V, Dereure O, Guilhou JJ. TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol 1994; 103: 102S-106S.
https://doi.org/10.1111/1523-1747.ep12399372 DOI: https://doi.org/10.1111/1523-1747.ep12399372
Pan W, Chai B, Li L, Lu Z, Ma Z. p53/MicroRNA-34 axis in cancer and beyond. Heliyon 2023; 9: e15155.
https://doi.org/10.1016/j.heliyon.2023.e15155 DOI: https://doi.org/10.1016/j.heliyon.2023.e15155
Lefort K, Brooks Y, Ostano P, Cario-André M, Calpini V, Guinea-Viniegra J, et al. A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J 2013; 32: 2248-2263.
https://doi.org/10.1038/emboj.2013.156 DOI: https://doi.org/10.1038/emboj.2013.156
Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
https://doi.org/10.1101/cshperspect.a001008 DOI: https://doi.org/10.1101/cshperspect.a001008
Italiano A, Chen CL, Thomas R, Breen M, Bonnet F, Sevenet N, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 2012; 118: 5878-5887.
https://doi.org/10.1002/cncr.27614 DOI: https://doi.org/10.1002/cncr.27614
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Kazunori Yokoi, Jing Wang, Yusuke Yoshioka, Yasuhiro Fujisawa, Manabu Fujimoto, Takahiro Ochiya, Atsushi Tanemura
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
